Citius Pharmaceuticals (CTXR) Expected to Announce Quarterly Earnings on Tuesday

Citius Pharmaceuticals (NASDAQ:CTXR) is expected to issue its Q2 2025 quarterly earnings data before the market opens on Tuesday, May 13th. Analysts expect Citius Pharmaceuticals to post earnings of $0.11 per share for the quarter.

Citius Pharmaceuticals (NASDAQ:CTXR) last issued its quarterly earnings data on Friday, February 14th. The company reported ($1.30) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.25) by ($0.05). On average, analysts expect Citius Pharmaceuticals to post $-5 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Citius Pharmaceuticals Price Performance

Citius Pharmaceuticals stock opened at $0.75 on Friday. Citius Pharmaceuticals has a fifty-two week low of $0.65 and a fifty-two week high of $26.25. The stock’s fifty day moving average is $1.16 and its two-hundred day moving average is $3.14.

Analyst Upgrades and Downgrades

Separately, D. Boral Capital reissued a “buy” rating and issued a $9.00 price objective on shares of Citius Pharmaceuticals in a research note on Tuesday, February 18th.

About Citius Pharmaceuticals

Citius Pharmaceuticals, Inc, a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome.